DCPH News and Press, Deciphera Pharmaceuticals Inc. From 01/08/24

– Preliminary Unaudited Fourth Quarter 2023 QINLOCK ® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and ...

2024-01-07 23:48:01 ET Summary Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor vimseltinib, with promising response rates in phase...

– Median Progression-Free Survival for QINLOCK ® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib – – Median Overall Survival for QINLOCK was Not Estimable Versus 1...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42...

2023-12-07 12:18:55 ET DENVER, Colo., Dec. 7, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cyngn Inc (NASDAQ: CYN), Save Foods Inc (NASDAQ: SVFD), Lilium NV (NASDAQ: LILM), Siyata Mobi...

2023-12-01 21:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a virtual fireside chat a...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

2023-10-31 13:49:23 ET More on Deciphera Pharmaceuticals Deciphera Pharmaceuticals Pipeline Is Underwhelming Deciphera Pharmaceuticals: Clawing Its Way Back Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call Transcript Deciphera stock climbs as tria...

Deciphera Pharmaceuticals Inc. (DCPH) is expected to report $-0.6 for Q3 2023